Wells Fargo analyst Mohit Bansal raised the firm’s price target on Vertex Pharmaceuticals to $425 from $410 and keeps an Overweight rating on the shares. The firm sees Vertex’s setup improving on approaching pipeline updates as acute pain and next-gen CF data are not far away. Timing of readouts was a key hang-up to owning Vertex in 2023, alongside slowing CF growth, and the company may have answers to both, Wells says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $370 from $360 at TD Cowen
- Vertex Pharmaceuticals price target raised to $390 from $380 at Bernstein
- Vertex Pharmaceuticals price target raised to $399 from $384 at Barclays
- Vertex Pharmaceuticals raises FY23 CF product revenue to $9.7B-$9.8B
- Vertex Pharmaceuticals reports Q2 EPS $3.52, consensus $3.88
Questions or Comments about the article? Write to editor@tipranks.com